バイオジェン・ジャパン（株）

What バイオジェン・ジャパン（株） does

Biogen Japan Ltd. (バイオジェン・ジャパン株式会社) is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. (NASDAQ: BIIB), a global neuroscience-focused biopharmaceutical company. The Japanese entity focuses on the development, registration, and commercialization of therapies for serious neurological and neurodegenerative diseases, with named franchises covering Alzheimer's disease (co-promoted with Eisai), amyotrophic lateral sclerosis (ALS), multiple sclerosis (co-promoted with Sanofi), and spinal muscular atrophy (co-promoted with Nippon Shinyaku / Japan Pharma). The company maintains a registered office in Nihonbashi, Chuo-ku, Tokyo, and is led by Representative Director and President 傳 幸晴 (Yukiharu Den). Its mission statement publicly emphasizes "patient-centered decisions" (患者さんが中心の決断), and its commercial activities are anchored in a co-promotion model that leverages the domestic sales infrastructure of established Japanese pharmaceutical partners rather than a fully independent salesforce.

The company's business model is a classic specialty-pharma distribution model: it licenses or originates therapies from the Biogen Inc. global pipeline, secures PMDA approval in Japan, and then distributes to hospitals, clinics, and specialty pharmacies through partner-led or hybrid sales channels. Revenue is generated through drug sales reimbursed under Japan's national health insurance system, with pricing subject to biennial NHI price revisions. Patient-facing engagement is delivered through disease-awareness campaigns (notably a nationwide TVCM for Mild Cognitive Impairment scheduled to begin May 1, 2026), patient-advocacy storytelling (e.g., Daiichi-san and Fuu-chan), and multi-channel social media presence on Facebook, Twitter, YouTube, and Instagram. The subsidiary has also extended beyond pure drug commercialization into a dedicated Digital Health division (バイオジェン・デジタルヘルス), signaling an intent to layer digital services, patient support tools, and potentially digital therapeutics on top of its pharmaceutical core. No standalone revenue, headcount, or R&D spend is publicly disclosed, as all material figures are consolidated into Biogen Inc.'s group reporting.

Name

バイオジェン・ジャパン（株）

Legal name

バイオジェン・ジャパン株式会社

Website

https://biogen.co.jp

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Biogen Japan is a Tokyo-headquartered, wholly-owned subsidiary of Biogen Inc. that develops and commercializes therapies for Alzheimer's, ALS, multiple sclerosis, and spinal muscular atrophy in the Japanese market, using co-promotion partnerships with Eisai, Sanofi, and Nippon Shinyaku for distribution.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals - Neurology and Rare Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Neurology therapeutics
• Biopharmaceutical products
• Rare disease treatments
• Digital health solutions
• Neuroscience biotechnology

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Prescription Pharmaceutical Products: Biogen Japan commercializes globally developed biopharmaceutical therapies for neurology, neuropsychiatry, specific immunology, and rare disease indications within Japan, generating revenue through product sales to hospitals, clinics, and pharmacies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Biogen Japan develops, registers, and commercializes prescription biopharmaceutical therapies for serious neurological and rare diseases in the Japanese market, with therapeutic focus on Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and spinal muscular atrophy (SMA). The company also operates a Biogen Digital Health division dedicated to individualized digital healthcare solutions in neuroscience. Revenue is generated through product sales to hospitals, clinics, and pharmacies via authorized wholesalers.

Product overview

Biogen is a science-led global biotechnology company that pushes the boundaries of science to develop innovative treatments for complex and serious diseases. The company operates across four key therapeutic areas: Alzheimer's disease, ALS (amyotrophic lateral sclerosis), Multiple Sclerosis, and Spinal Muscular Atrophy. Additionally, Biogen Japan has a dedicated Digital Health division (バイオジェン・デジタルヘルス) focused on individualized digital healthcare solutions in neuroscience. The company also maintains collaborative relationships with other pharmaceutical companies including Sanofi, Eisai, and Nippon Shinyaku for purposes such as joint seminars, disease awareness, and safety information management.

Differentiator

Problem solved

Functional benefit

Products and services

• Alzheimer's Disease Treatment (アルツハイマー病治療) Prescription biopharmaceutical therapy for Alzheimer's disease, a neurodegenerative condition affecting memory and cognitive function, offered to neurologists and specialized memory clinics in Japan.
• ALS (Amyotrophic Lateral Sclerosis) Treatment (筋萎縮性側索硬化症治療) Prescription therapy for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting motor nerve cells, targeted at neurologists and ALS-specialized centers in Japan.
• Multiple Sclerosis (MS) Treatment (多発性硬化症治療) Prescription therapy for multiple sclerosis (MS), a chronic condition affecting the central nervous system, offered to neurologists and MS-specialized hospitals in Japan.
• Spinal Muscular Atrophy (SMA) Treatment (脊髄性筋萎縮症治療) Prescription therapy for spinal muscular atrophy (SMA), a genetic disorder causing muscle weakness and atrophy, offered to neurologists and pediatric neuromuscular specialists in Japan.
• Biogen Digital Health (バイオジェン・デジタルヘルス) A digital health initiative within Biogen Japan focused on achieving individualized digital healthcare in neuroscience, aimed at transforming patient lives and Biogen's business through digital tools and solutions.

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Sanofi (サノフィ株式会社)coreGTM or Marketing PartnerSanofi and Biogen Japan jointly utilize healthcare professional personal data for co-hosted seminars, speaker invitations, and disease awareness campaigns targeting healthcare professionals in Japan. Data management responsibility lies with Biogen Japan.
• Japan Pharma (日本新薬株式会社)coreGTM or Marketing PartnerJapan Pharma collaborates with Biogen Japan on co-promotion activities and healthcare professional engagement related to disease awareness and product information in Japan.
• Eisai (エーザイ株式会社)coreGTM or Marketing PartnerEisai and Biogen Japan share healthcare professional data for disease awareness, medical product information provision, treatment support, adverse event safety information management, and post-marketing surveillance in Japan.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Otsuka Pharmaceutical Co., Ltd. Major Japanese pharma with a CNS/psychiatry franchise (e.g., aripiprazole and related products). Comparable to Biogen Japan in targeting the same neurology/psychiatry specialist channel and in using co-promotion-style commercial models in Japan.
• Eisai Co., Ltd. Japanese global pharma with a leading neuroscience franchise, most notably lecanemab (Leqembi) for Alzheimer's disease. Direct competitor to Biogen Japan in CNS and Alzheimer's, while simultaneously a co-promotion partner, making it the most directly comparable peer.
• Sanofi K.K. Global biopharma with multiple sclerosis and rare disease franchises (e.g., teriflunomide/Aubagio). Both a co-promotion partner to Biogen Japan and a direct competitor in MS and rare neurological indications in Japan.
• Novartis Pharma K.K. (Japan): Operates in Japan's neurology/MS space (e.g., MS therapies) and is a major multinational biopharma with neuroscience exposure. Comparable to Biogen Japan in product category (specialty neurology biologics) and in serving similar specialist HCPs in Japan.
• Sumitomo Pharma Co., Ltd. Japanese specialty pharma with a strong CNS/psychiatry pipeline (e.g., latuda, regenerative medicine programs). Competes with Biogen Japan in the same specialist neurology and psychiatry prescriber base in Japan.

Broad incumbents

• Takeda Pharmaceutical Company Limited: Japan's largest pharma with broad neuroscience, rare disease, and plasma-derived therapy franchises. A larger, broadly diversified incumbent with overlapping neurology/rare-disease capability but a much wider portfolio than Biogen Japan.
• Daiichi Sankyo Co., Ltd. Major Japanese pharma with broad therapeutic areas including neurology adjacencies. While not as CNS-focused as Biogen Japan, it competes for the same specialty-pharma talent, HCP relationships, and co-promotion partners in Japan.
• Chugai Pharmaceutical Co., Ltd. A Roche-group Japanese biopharma with strong specialty/biologics capabilities (e.g., NMOSD therapy). Comparable in being a Japan-resident biopharma with biologics-heavy product mix and similar regulatory/commercial dynamics.

Emerging players

• UCB Japan (UCB S.A.): Specialty neurology biopharma with strong presence in epilepsy and rare disease in Japan (e.g., Vimpat, Briviact). Comparable as a specialty/CNS-focused player with concentrated therapeutic-area depth in Japan rather than broad pharma scale.
• Kyowa Kirin Co., Ltd. Japanese specialty biopharma focused on rare diseases and specialty immunology/neurology (e.g., HLH, rare metabolic). A smaller, focused Japanese peer with rare-disease specialty model comparable to Biogen Japan's SMA franchise approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/%E3%83%90%E3%82%A4%E3%82%AA%E3%82%B8%E3%82%A7%E3%83%B3%E3%83%BB%E3%82%B8%E3%83%A3%E3%83%91%E3%83%B3%EF%BC%88%E6%A0%AA%EF%BC%89

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about バイオジェン・ジャパン（株）